Real-Time Optical Biopsy in Improving Lung Cancer Diagnosis in Patients Undergoing Lung Biopsy



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/27/2018
Start Date:July 26, 2017
End Date:November 1, 2021
Contact:Charles Hennemeyer, MD
Email:cth@radiology.arizona.edu
Phone:520-626-1957

Use our guide to learn which trials are right for you!

Real-Time Optical Biopsy for Improved Lung Cancer Diagnosis

This pilot early phase I trial studies how well real-time optical biopsy works in improving
lung cancer diagnosis in patients undergoing lung biopsy. Real-time optical biopsy using
confocal microscopy may improve the ability of physicians to diagnose lung cancer and
accurately differentiate cancerous and benign lesions found during computed tomography
screening.

PRIMARY OBJECTIVES:

I. Show that it is possible to distinguish lung cancer from benign lesions in ex vivo tissue
samples using optical microscopy.

II. Test a proof-of-concept endoscopic instrument for imaging through a biopsy needle under
computed tomography (CT) guidance on ex vivo tissue samples.

OUTLINE:

Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are
at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax
needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety
of fluorescent contrast agents, such as, fluorescein sodium, methylene blue, or indocyanine
green and then undergo hematoxylin and eosin processing.

Inclusion Criteria:

- Participants will be drawn from the pool of patients who have suspicious lesions
identified on CT and who are already scheduled for a lung biopsy procedure with Dr.
Hennemeyer or one of his colleagues

- Patients will be asked to consent to 2 to 3 extra biopsy samples to be used for this
research project

Exclusion Criteria:

- Excluded from this study will be prisoners, pregnant women, patients with a
contraindication for additional lung biopsies, and patients who cannot give informed
consent (language barrier, cognitive impairment, etc.)
We found this trial at
1
site
Tucson, Arizona 85721
(520) 621-2211
Principal Investigator: Charles Hennemeyer, MD
Phone: 520-626-1957
University of Arizona The University of Arizona is a premier, public research university. Established in...
?
mi
from
Tucson, AZ
Click here to add this to my saved trials